Should prolactin be reconsidered as a therapeutic target in human breast cancer?

[1]  J. Martial,et al.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Martial,et al.  Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. , 1998, Endocrinology.

[3]  B. Vonderhaar.  Prolactin: the forgotten hormone of human breast cancer. , 1998, Pharmacology & therapeutics.

[4]  H. van Essen,et al.  Angiogenic potential of malignant and non‐malignant human breast tissues in an in vivo angiogenesis model , 1998, International journal of cancer.

[5]  K. Pritchard.  Is tamoxifen effective in prevention of breast cancer? , 1998, The Lancet.

[6]  J. Grosclaude,et al.  Novel Recombinant Analogues of Bovine Placental Lactogen , 1998, The Journal of Biological Chemistry.

[7]  P. Kelly,et al.  Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. , 1998, Endocrine reviews.

[8]  D. Yee,et al.  Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells* , 1998, The Journal of Biological Chemistry.

[9]  M. Waters,et al.  Cellular expression of growth hormone and prolactin receptors in human breast disorders , 1998, International journal of cancer.

[10]  P. Kelly,et al.  Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[11]  A. Walker,et al.  Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. , 1998, Endocrinology.

[12]  B. van der Burg,et al.  Mitogenic Signaling of Insulin-like Growth Factor I in MCF-7 Human Breast Cancer Cells Requires Phosphatidylinositol 3-Kinase and Is Independent of Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[13]  C. Ohlsson,et al.  Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. , 1997, The Journal of clinical investigation.

[14]  C. Powell,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Expression of Prolactin and Its Receptor in Human Breast Carcinoma* , 2022 .

[15]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[16]  R. Snell,et al.  Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Levitzki,et al.  Tyrphostin AG 494 blocks Cdk2 activation , 1997, FEBS letters.

[18]  T. Mustelin,et al.  Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Kelly,et al.  The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor , 1997, Molecular and Cellular Endocrinology.

[20]  L. Hennighausen,et al.  Stat5a is mandatory for adult mammary gland development and lactogenesis. , 1997, Genes & development.

[21]  P. Kelly,et al.  Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. , 1997, Genes & development.

[22]  N. Ben-Jonathan,et al.  Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. , 1996, Endocrine reviews.

[23]  B. Vonderhaar,et al.  Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. , 1996, Oncogene.

[24]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[25]  J. Martial,et al.  Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen, and related proteins in mammals. , 1996, Endocrine reviews.

[26]  Enrico A. Stura,et al.  Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.

[27]  J. Martial,et al.  Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay* , 1996, The Journal of Biological Chemistry.

[28]  H. Rui,et al.  Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580 , 1996, Molecular and Cellular Endocrinology.

[29]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[30]  J A Wells,et al.  Binding in the growth hormone receptor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[32]  N. Ben-Jonathan,et al.  Prolactin is a local growth factor in rat mammary tumors. , 1995, Endocrinology.

[33]  J. Martial,et al.  Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Vonderhaar,et al.  Prolactin synthesis and secretion by human breast cancer cells. , 1995, Cancer research.

[35]  G. Fuh,et al.  Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines (*) , 1995, The Journal of Biological Chemistry.

[36]  Y. Sinha.  Structural variants of prolactin: occurrence and physiological significance. , 1995, Endocrine reviews.

[37]  A. Ullrich,et al.  Proline-rich Sequence-mediated Jak2 Association to the Prolactin Receptor Is Required but Not Sufficient for Signal Transduction (*) , 1995, The Journal of Biological Chemistry.

[38]  A. Harris,et al.  Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Tomaszewski,et al.  Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. , 1995, The American journal of pathology.

[40]  I. Kerr,et al.  Jaks and Stats in signaling by the cytokine receptor superfamily. , 1995, Trends in genetics : TIG.

[41]  J. Martial,et al.  Evidence for a second receptor binding site on human prolactin. , 1994, The Journal of biological chemistry.

[42]  T. Wagner,et al.  In vitro and in vivo studies of antagonistic effects of human growth hormone analogs. , 1994, The Journal of biological chemistry.

[43]  P. De Meyts,et al.  Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. , 1994, Endocrinology.

[44]  A. Ullrich,et al.  Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. , 1994, The Journal of biological chemistry.

[45]  J. Martial,et al.  Characterization of an up-stream promoter directing extrapituitary expression of the human prolactin gene. , 1994, Molecular endocrinology.

[46]  B. Gellersen,et al.  Nonpituitary human prolactin gene transcription is independent of Pit-1 and differentially controlled in lymphocytes and in endometrial stroma. , 1994, Molecular endocrinology.

[47]  E. Hooghe-Peters,et al.  Pit-1/GHF-1 expression in pituitary adenomas: further analogy between human adenomas and rat SMtTW tumours. , 1993, Journal of molecular endocrinology.

[48]  J. Martial,et al.  The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. , 1993, Endocrinology.

[49]  O. Silvennoinen,et al.  Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase , 1993, Cell.

[50]  E. Hooghe-Peters,et al.  The transcription factor Pit‐l/GHF‐1 is expressed in hemopoietic and lymphoid tissues , 1993, European journal of immunology.

[51]  W. Wood,et al.  Mechanism-based design of prolactin receptor antagonists. , 1993, The Journal of biological chemistry.

[52]  W. Willett,et al.  Breast cancer (1) , 1992, The New England journal of medicine.

[53]  P. Kelly,et al.  Expression of prolactin and its receptor in human lymphoid cells. , 1992, Molecular endocrinology.

[54]  D. Goeddel,et al.  Rational design of potent antagonists to the human growth hormone receptor. , 1992, Science.

[55]  R. Weiner,et al.  A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. , 1992, Endocrinology.

[56]  M. Ultsch,et al.  Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. , 1992, Science.

[57]  N. Ferrara,et al.  The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. , 1991, Endocrinology.

[58]  B. Gellersen,et al.  Human prolactin gene expression. The use of an alternative noncoding exon in decidua and the IM-9-P3 lymphoblast cell line. , 1990, The Journal of biological chemistry.

[59]  P. Kelly,et al.  Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family , 1988, Cell.

[60]  D. Chalbos,et al.  Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. , 1983, The Journal of clinical endocrinology and metabolism.

[61]  W. Malarkey,et al.  Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture. , 1983, The Journal of clinical endocrinology and metabolism.

[62]  P. Gullino,et al.  Neovascularization induced by intraocular xenografts of normal, preneoplastic, and neoplastic mouse mammary tissues. , 1976, Journal of the National Cancer Institute.

[63]  Y. J. Topper,et al.  Multiple hormone interactions in the development of mammary gland in vitro. , 1970, Recent progress in hormone research.